Stockholm3 in combination with MRI enables implementation of population-based screening of prostate cancer The combination decreases unnecessary biopsies by 74 percent STOCKHOLM, August 13, 2021. A3P Biomedical AB today announced that the publication of the STHLM3 MRI trial including 12,750 men has been fast tracked and is now published…
An abstract presenting the STHLM3 MR trial was awarded the “1st Prize Best Abstract Oncology 2021” at the annual European Association of Urology meeting. The trial included 12,750 men and concluded that combining the Stockholm3 test with MRI for prostate cancer screening decreases overdetection by 69 percent compared to…
STOCKHOLM, June 18, 2021. A3P Biomedical appoints David Rosén as new CEO to lead the commercial expansion of the company’s novel Stockholm3 test for early detection of prostate cancer. David brings more than 20 years’ experience from the medical device industry, including senior international positions at Getinge and Cantel…
STOCKHOLM, March 19, 2021. A3P Biomedical announced today that an independent and peer reviewed study showed health economic benefits using Stockholm3 versus PSA in a screening by invitation setting for prostate cancer. The results from the study demonstrated that Stockholm3 reduced unnecessary biopsies and was cost-effective compared to…
STOCKHOLM, January 10, 2021. A3P Biomedical strengthens the management team with Marianne Waplan as CFO, Marcela Björn as Director of Marketing & Sales and Malin Gidlund as Head of Lab Operations preparing for the company’s international expansion. “In order to realize A3P Biomedical’s growth opportunities, we are building a…
